Back to top
more

Alphatec (ATEC)

(Delayed Data from NSDQ)

$13.77 USD

13.77
12,996,487

+3.19 (30.15%)

Updated Aug 1, 2025 04:00 PM ET

After-Market: $13.76 -0.01 (-0.07%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 36% (158 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Alphatec (ATEC) Beats Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Alphatec (ATEC) delivered earnings and revenue surprises of +133.33% and +3.65%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Alphatec (ATEC) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Alphatec (ATEC) delivered earnings and revenue surprises of -91.67% and 0.23%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

VEEV Stock Up as Q4 Earnings & Revenues Beat Estimates, Margin Rise

by Zacks Equity Research

Veeva Systems' fiscal fourth-quarter results reflect impressive performance by the Subscription services segment, along with the expansion of gross and operating margins.

Zacks Equity Research

Nevro Q4 Earnings & Revenues Beat Estimates, Gross Margin Down

by Zacks Equity Research

NVRO's fourth-quarter earnings surpass the Zacks Consensus Estimate, while worldwide revenues decline year over year. The company continues to incur losses at the operating level.

Zacks Equity Research

Here's Why You Should Hold Accuray Stock in Your Portfolio for Now

by Zacks Equity Research

ARAY continues to witness strength in its flagship CyberKnife system, along with robust global performance.

Zacks Equity Research

STXS Stock Tumbles Despite EMAGIN Catheter Submission for Approval

by Zacks Equity Research

Stereotaxis submits EMAGIN 5F, a robotic catheter, for regulatory clearance.

Zacks Equity Research

Owens & Minor Shares Surge 39% on Earnings Beat and Growth Plans

by Zacks Equity Research

OMI's shares witnessed a massive uptick after the company posted stronger-than-expected Q4 earnings. Its strategic focus on Patient Direct and the Rotech acquisition indicates long-term shareholder value.

Zacks Equity Research

GEHC Stock May Rise on Freelium Magnet Launch, Boosts MR Access

by Zacks Equity Research

GE HealthCare unveils Freelium, a next-gen sealed magnet platform designed to revolutionize MR imaging with minimal helium usage.

Zacks Equity Research

GKOS Crashes Almost 25% After Q4 Earnings: How to Play the Stock?

by Zacks Equity Research

Glaukos reported robust fourth-quarter revenues, but shares plunged 24.8% post-earnings. Can expanding iDose TR adoption and global growth offset competitive pressures and valuation concerns in 2025?

Zacks Equity Research

CLOV Q4 Earnings Beat Estimates, Sales Miss, Membership Rises

by Zacks Equity Research

Clover Health's fourth-quarter 2024 results continue to benefit from the strength of its strong member retention. Strong revenue outlook bodes well.

Zacks Equity Research

Can ITGR Stock's Growth Drivers Offset Rising Risks in 2025?

by Zacks Equity Research

Integer Holdings projects 8-10% sales growth in 2025, driven by acquisitions and high-demand medical technologies. But, can it overcome tariff and margin pressures?

Zacks Equity Research

PDCO Q3 Earnings & Sales Miss Estimates, Margins Contract

by Zacks Equity Research

Patterson Companies' overall top-line figure for the third quarter of fiscal 2025 reflects weak segmental performance.

Zacks Equity Research

Alphatec (ATEC) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Alphatec (ATEC) delivered earnings and revenue surprises of -27.78% and 1.94%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Fresenius Medical Q4 Earnings Beat Estimates, Revenues Up Y/Y

by Zacks Equity Research

FMS' fourth-quarter results showcase a strong segmental performance along with providing full year 2025 outlook for revenue growth and operating income.

Zacks Equity Research

INGN Stock Gains Following Q4 Earnings Beat, Adjusted Gross Margin Up

by Zacks Equity Research

Inogen's overall fourth-quarter 2024 results continue to gain from higher business-to-business sales.

Zacks Equity Research

Tempus Stock Falls as Q4 Earnings & Revenues Miss Estimates

by Zacks Equity Research

TEM's fourth-quarter results reflect strong segmental performance. However, the company continues to incur losses at the operational level.

Zacks Equity Research

Integra LifeSciences (IART) Surpasses Q4 Earnings Estimates

by Zacks Equity Research

Integra (IART) delivered earnings and revenue surprises of 14.12% and 0.45%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

GKOS Stock Falls Despite Q4 Earnings & Revenue Beat, Margins Decline

by Zacks Equity Research

Glaukos' fourth-quarter results showcase a strong uptick in revenues. However, continued operating loss and rising OpEx remain a cause of concern.

Zacks Equity Research

Quest Diagnostics Stock to Gain From Innovation Amid Industry Threats

by Zacks Equity Research

Within brain health, the robust demand for AD-detect blood tests for assessing Alzheimer's disease risk drives solid growth for DGX in the fourth quarter of 2024.

Zacks Equity Research

Here's Why You Should Retain Glaukos Stock in Your Portfolio Now

by Zacks Equity Research

GKOS continues to benefit from robust product demand and expansion in new markets. A strong development pipeline raises optimism.

Zacks Equity Research

Has Boston Scientific (BSX) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Boston Scientific (BSX) and Alphatec (ATEC) have performed compared to their sector so far this year.

Zacks Equity Research

Here's Why You Should Add Inogen Stock to Your Portfolio Now

by Zacks Equity Research

Expanding product portfolio and high prospects for POC raise optimism for INGN stock.

Zacks Equity Research

Alphatec (ATEC) Moves 9.1% Higher: Will This Strength Last?

by Zacks Equity Research

Alphatec (ATEC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks Equity Research

Wall Street Analysts Predict a 73.42% Upside in Alphatec (ATEC): Here's What You Should Know

by Zacks Equity Research

The consensus price target hints at a 73.4% upside potential for Alphatec (ATEC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks Equity Research

Should You Invest in the SPDR S&P Health Care Equipment ETF (XHE)?

by Zacks Equity Research

Sector ETF report for XHE